Shopping Cart 0
Cart Subtotal
USD 0

Serodus ASA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Serodus ASA (Serodus) is a drug development company that develops treatments for unmet clinical needs in the areas of diabetes and diabetic comorbidities. The company's pipeline products include SER150DN, an anti-inflammatory compound under development for diabetic nephropathy; SER130AMI, an interleukin-4 agonist for acute myocardial infarction; SER100PH, for group I or IV pulmonary hypertension; SER140T2D; and SER190DFU. Its pipeline product SER190 is an IL-1beta receptor antagonist IL-1Ra, which provide wound healing with biological process in three phases such as inflammation, proliferation and maturation. The company enters into licensing arrangements and collaborates with biotech companies and universities to develop its product pipeline. Serodus is headquartered in Oslo, Norway.

Serodus ASA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Serodus ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Serodus ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Serodus ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Serodus ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Serodus ASA, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Serodus Raises USD 0.09 Million In Venture Financing 10

Licensing Agreements 11

Evolva And Serodus Enter Into Licensing Agreement For EV-077 11

Equity Offering 12

Serodus Raises USD1.2 Million in Private Placement of Shares 12

Serodus to Raise up to USD3.7 Million in Rights Offering of Shares 13

Serodus Completes Public Offering of Shares for USD1.71 Million 14

Serodus Completes Private Placement Of Shares For USD 4.9 Million 15

Serodus Completes IPO Of USD 0.7 Million 16

Acquisition 18

Viggo Harboe Holding 2006 to Acquire Additional 8.1% Stake in Serodus 18

Serodus Completes Acquisition of Phlogo for USD0.9 Million 19

Serodus ASA-Key Competitors 20

Serodus ASA-Key Employees 21

Serodus ASA-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Feb 27, 2017: Serodus: Results for Q4-2016 23

Appendix 24

Methodology 24

About GlobalData 24

Contact Us 24

Disclaimer 24


List Of Figure

List of Figures

Serodus ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Serodus ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Serodus ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Serodus ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Serodus ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Serodus ASA, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Serodus ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Serodus ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Serodus ASA, Deals By Therapy Area, 2012 to YTD 2018 8

Serodus ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Serodus Raises USD 0.09 Million In Venture Financing 10

Evolva And Serodus Enter Into Licensing Agreement For EV-077 11

Serodus Raises USD1.2 Million in Private Placement of Shares 12

Serodus to Raise up to USD3.7 Million in Rights Offering of Shares 13

Serodus Completes Public Offering of Shares for USD1.71 Million 14

Serodus Completes Private Placement Of Shares For USD 4.9 Million 15

Serodus Completes IPO Of USD 0.7 Million 16

Viggo Harboe Holding 2006 to Acquire Additional 8.1% Stake in Serodus 18

Serodus Completes Acquisition of Phlogo for USD0.9 Million 19

Serodus ASA, Key Competitors 20

Serodus ASA, Key Employees 21

Serodus ASA, Subsidiaries 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Serodus ASA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.